Phase I double-blind RCT in 70 adults aged 18-50 previously given ≥3 mRNA COVID-19 vaccine doses: a single booster of the MC2-clamp spike subunit vaccine UQSC2 was as well tolerated as NVX-CoV2373 and gave comparable neutralising responses to the Wuhan strain.
RCTn = 70
Chappell et al. Safety and Immunogenicity of a Severe Acute Respiratory Syndrome Coronavirus 2 Spike Subunit Vaccine Stabilized in the Prefusion Conformation by a Second-Generation Molecular Clamp and Evaluated in Adults Aged 18-55 Years: A Randomized, Double-Blind, Active Comparator, Phase I Trial